{
  "docId": "019de075-e109-770f-8f32-3054686041b6",
  "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Spyre Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 38,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The chart uses a stacked bar to visualize the additive nature of the combination therapy compared to the individual components.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/30",
  "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
  "deckJsonHref": "/decks/019de075-e109-770f-8f32-3054686041b6.json",
  "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.68,
        "y": 0.78
      },
      "kind": "callout",
      "text": "PROBABLE BLACK BOX",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55e4607f-1d24-4704-ab25-df0eda56797b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.18,
        "y": 0.78
      },
      "kind": "callout",
      "text": "BLACK BOX WARNING",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea236bc1-78ff-4c76-8d30-62277882872c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.7,
        "x": 0.15,
        "y": 0.2
      },
      "kind": "chart",
      "text": "VEGA Combination Study (N=71/arm) showing 25% (Anti-TNF), 24% (Anti-IL23), and 47% (Combination)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5b26445-8caf-4b7c-bf34-4936634454eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.96,
        "x": 0.02,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "NOTE: In VEGA, only guselkumab (IL-23) was continued in maintenance for the combo arm in a treat-through design; Spyre plans to use combinations in maintenance. Maintenance remission rates for the anti-TNF arm, anti-IL23 arm, and induction combination arm were 28%, 31%, and 48%, respectively.; Feagan, B. G. et al. Lancet Gastroenterol. Hepatol. 8, 307–320 (2023).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10f07a12-7c3a-49c8-99b6-5acefba9bb8e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "JNJ's VEGA study demonstrated power of combination therapy despite relative weakness of components",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "340724d5-106e-4e1d-a217-90494f72aa26",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "9997df60-0053-410a-9cca-aa0cb23a3388",
      "evidence": "not clearly visible",
      "confidence": 0.5
    },
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "fd322eba-62d6-4602-9352-01ca71b636e9",
      "evidence": "comparison_table showing 25% (Anti-TNF), 24% (Anti-IL23), and 47% (Combination)",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "44e0b3ba-0ba6-45da-a645-65dd4f248afe",
      "evidence": "Comparing individual therapy performance against combination therapy performance.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}